What We're Reading: Page 210
Industry reads hand-picked by our editors
Aug 29, 2019
-
The Wall Street Journal
New Concerns Emerge About Long-Term Antidepressant Use
-
Associated Press
Pinterest to direct vaccine-related searches to health orgs
-
Reuters
Roche immunotherapy Tecentriq gains European approval for breast cancer
Aug 28, 2019
-
The New York Times
Johnson & Johnson's Brand Falters Over Its Role in the Opioid Crisis
-
Vantage
Six burning Otezla questions
-
Kaiser Health News
Beset by lawsuits and criticism in U.S., opioid makers eye new market in India
-
The Oklahoman
Cannabisville, Oklahoma: The ZIP code with most business licenses
Aug 27, 2019
Aug 26, 2019
-
STAT
They rallied around 'our boys' with Duchenne. Where did that leave girls?
-
The New York Times
The $6 Million Drug Claim
-
The Wall Street Journal
New Details Emerge Over Mallinckrodt’s Role in Opioid Crisis
Aug 23, 2019
-
MIT Technology Review
The next trick for CRISPR is gene-editing pain away
-
The New York Times
Life-Changing Drugs Almost Nobody Can Afford
-
The Wall Street Journal
Customers Handed Over Their DNA. The Company Let the FBI Take a Look.
Aug 22, 2019
-
Bloomberg
Health Investment Firm OrbiMed Growing Wary of a Tougher FDA
-
The Wall Street Journal
Time to Throw In the Towel on Biosimilars
-
BioCentury
Biomedical stakeholders caution against limiting U.S.-China collaboration
-
Washington Post
Gilead files challenge to government patents for HIV prevention pill
Previous
